HIV Infection Clinical Trial
Official title:
Drug Use and HIV-Infected Female Adolescents' Care Use
| Verified date | August 2016 |
| Source | University of North Carolina, Chapel Hill |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Observational |
The proposed multi-site, longitudinal study will examine the correlation of substance use, mental health disorders, and social networks to engagement in care for HIV-infected adolescent females, aged 13 years, 0 months - 23 years, 11 months, and suggest ways to promote adherence and retention in treatment, care, and prevention programs. Qualitative and quantitative data collection methods will be used with index participants and network members.
| Status | Completed |
| Enrollment | 178 |
| Est. completion date | December 2010 |
| Est. primary completion date | December 2010 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 13 Years to 23 Years |
| Eligibility |
Quantitative Study Inclusion Criteria Index Participants: 1. Female. 2. Age 13 years, 0 months - 23 years, 11 months (364 days). 3. All race/ethnicities. 4. English or Spanish speaking. 5. Non-perinatal, non-transfusion acquired HIV. 6. Unknown transmission status with study personnel approval. Network Participants: Parents/Guardians of Index Participants: 1. Know patient's HIV status 2. Male or female. 3. All race/ethnicities 4. English or Spanish speaking. 5. Serve a parental or guardian-like role. Close Friend of Index Participants: 1. Close friend of index subject. 2. Male or female. 3. Minimum age 13 years, 0 months. 4. All race/ethnicities 5. English or Spanish speaking Ethnographic Sub-Sample Inclusion Criteria: Index Participants: 1. Enrolled in Quantitative NIDA study. 2. English-speaking at Miami, New York, Chicago, and New Orleans sites. 3. English or Spanish-speaking at Los Angeles USC site Network Participants: 1. English-speaking at Miami, New York, Chicago, and New Orleans sites. 2. English or Spanish-speaking at Los Angeles USC site. 3. Know index serostatus. Gender Sub-Sample Inclusion Criteria: 1. Age 18 years, 0 months - 23 years, 11 months. 2. Enrolled in quantitative study. 3. English-speaking. 4. Female. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Montefiore Medical Center | Bronx | New York |
| United States | Stroger Hospital of Cook County | Chicago | Illinois |
| United States | Universtiy of Southern California | Los Angeles | California |
| United States | University of Miami, School of Medicine | Miami | Florida |
| United States | Tulane Medical Center | New Orleans | Louisiana |
| Lead Sponsor | Collaborator |
|---|---|
| University of North Carolina, Chapel Hill | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute on Alcohol Abuse and Alcoholism (NIAAA), National Institute on Drug Abuse (NIDA) |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Engagement in Care among Index Participants | Engagement in care will be operationalized as the number of clinic visits attended and will be assessed through the qualitative interviews. | Baseline, 6 months, 12 months, and 18 months | |
| Secondary | Medication Adherence | As assessed through the qualitative interviews for index and network participants. | Baseline, 6 months, 12 months, and 18 months | |
| Secondary | Sexual Risk Behaviors | As assessed through the qualitative interviews for index and network participants. | Baseline, 6 months, 12 months, and 18 months | |
| Secondary | Substance Use | As assessed through the qualitative interviews for index and network participants. | Baseline, 6 months, 12 months, and 18 months |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
| Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
| Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
| Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
| Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
| Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
| Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
| Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
| Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
| Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
| Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
| Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
| Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
| Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
| Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
| Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
| Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
| Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
| Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
| Completed |
NCT01680094 -
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
|
Phase 1/Phase 2 |